Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse...

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Diffuse large B-cell lymphoma (DLBCL) patients often lack durable responses to bispecific antibodies (BsAb) and chimeric antigen receptor (CAR) T cells.
• Understanding the tumor immune microenvironment is crucial for improving DLBCL treatment efficacy.

Approach:

• An integrative, multi-omic strategy was used to analyze DLBCL immune environments.
• DLBCLs were classified into four distinct DLBCL-immune quadrants (IQ) based on cell-of-origin and immune gene expression scores.
• Genomic alterations were correlated with IQ classifications to understand their role in shaping the immune microenvironment.

Key Points:

• DLBCL-IQ classification revealed distinct immune microenvironments within DLBCL subtypes.
• Recurrent genomic alterations were associated with specific DLBCL-IQ classifications.
• In relapsed/refractory DLBCL patients, DLBCL-IQ assignment predicted clinical benefit from the CD20 x CD3 BsAb, mosunetuzumab.
• DLBCL-IQ assignment did not correlate with clinical benefit from CD19-directed CAR T cells.

Conclusions:

• The DLBCL-IQ framework offers a new way to understand the DLBCL immune landscape.
• The endogenous immune environment differentially impacts treatment outcomes for BsAb and CAR T cell therapies.
• This research highlights the importance of immune microenvironment characterization for personalized DLBCL treatment strategies.